MEG3: A novel long noncoding potentially tumour-suppressing RNA in meningiomas

Journal of Neuro-Oncology

Volumn 112, Issue 1, 2013, Pages 1-8

  Balik, Vladimir ^a   Srovnal, Josef ^b   Sulla, Igor ^c   Kalita, Ondrej ^a   Foltanova, Tatiana ^d   Vaverka, Miroslav ^a   Hrabalek, Lumir ^a   Hajduch, Marian ^b  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF VETERINARY MEDICINE   (Slovakia)

^d Physics and Informatics   (Slovakia)

Author keywords

Maternally Expressed Gene 3; Meningiomas; Non coding RNA

Indexed keywords

CYCLIC AMP; GENOMIC DNA; GROWTH DIFFERENTIATION FACTOR; MICRORNA; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNTRANSLATED RNA;

ANGIOGENESIS; CAMP GENE; CANCER GROWTH; CARCINOGENESIS; CHROMOSOME 14Q; CHROMOSOME LOSS; CONTROLLED STUDY; DLK1 GENE; DNA METHYLATION; GDF15 GENE; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GENE LOSS; GENE STRUCTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; MDM2 GENE; MEG3 GENE; MENINGIOMA; NEUROBLASTOMA; NONHUMAN; PHEOCHROMOCYTOMA; PROMOTER REGION; RB1 GENE; REVIEW; TUMOR SUPPRESSOR GENE; UPREGULATION;

BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 14; HUMANS; MENINGIOMA; NEOVASCULARIZATION, PATHOLOGIC; RNA, LONG UNTRANSLATED; SIGNAL TRANSDUCTION;

EID: 84872006379     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-1038-6     Document Type: Review

References (76)

1. Cushing H (1922) The meningiomas (dural endotheliomas): their source and favored seats of origin. Brain 45:282-316
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109 (Pubitemid 47103521)
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO classifcation of tumours of the central nervous system. IARC, Lyon
4. Perry ALD, Scheithauer BW, Budka H, von Deimling A (2007) Menigiomas. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system. International Agency for Research on Cancer, Lyon
5. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL (1985) Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 62:18-24 (Pubitemid 15199399)
6. Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K (2000) Recurrence of meningiomas. Cancer 89:1102-1110
7. Jaaskelainen J (1986) Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol 26:461-469 (Pubitemid 16006137)
8. Aghi M, Carter B, Cosgrove G, Ojemann R, Amin-Hanjani S, Martuza R, Curry WT Jr, Barker FG 2nd (2009) Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 64:56-60
9. Simon M, von Deimling A, Larson JJ, Wellenreuther R, Kaskel P, Waha A, Warnick RE, Tew JM Jr, Menon AG (1995) Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res 55:4696-4701
10. Weber RG, Bostrom J, Wolter M, Baudis M, Collins VP, Reifenberger G, Lichter P (1997) Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 94:14719-14724 (Pubitemid 28041440)
11. Menon AG, Rutter JL, von Sattel JP, Synder H, Murdoch C, Blumenfeld A, Martuza RL, von Deimling A, Gusella JF, Houseal TW (1997) Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative 'tumor progression' locus. Oncogene 14:611-616 (Pubitemid 27090964)
12. Cai DX, Banerjee R, Scheithauer BW, Lohse CM, Kleinschmidt-Demasters BK, Perry A (2001) Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications. J Neuropathol Exp Neurol 60:628-636 (Pubitemid 32523627)
13. Zhang X, Gejman R, Mahta A, Zhong Y, Rice KA, Zhou Y, Cheunsuchon P, Louis DN, Klibanski A (2010) Maternally Expressed Gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res 70:2350-2358
14. Miyoshi N, Wagatsuma H, Wakana S, Shiroishi T, Nomura M, Aisaka K, Kohda T, Surani MA, Kaneko-Ishino T, Ishino F (2000) Identification of an imprinted gene, Meg3/Gtl2 and its human homologue MEG3, first mapped on mouse distal chromosome 12 and human chromosome 14q. Genes Cells 5:211-220 (Pubitemid 30227843)
15. Wylie AA, Murphy SK, Orton TC, Jirtle RL (2000) Novel imprinted DLK1/GTL2 domain on human chromosome 14 contains motifs that mimic those implicated in IGF2/H19 regulation. Genome Res 10:1711-1718
16. Schuster-Gossler K, Bilinski P, Sado T, Ferguson-Smith A, Gossler A (1998) The mouse Gtl2 gene is differentially expressed during embryonic development, encodes multiple alternatively spliced transcripts, and may act as an RNA. Dev Dyn 212:214-228 (Pubitemid 28265141)
17. Mattick JS, Makunin IV (2005) Small regulatory RNAs in mammals. Hum Mol Genet 14:R121-R132 (Pubitemid 40542628)
18. Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, Klibanski A (2003) A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab 88:5119-5126 (Pubitemid 37452705)
19. Astuti D, Latif F, Wagner K, Gentle D, Cooper WN, Catchpoole D, Grundy R, Ferguson-Smith AC, Maher ER (2005) Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour. Br J Cancer 92:1574-1580 (Pubitemid 40705027)
20. Zhao J, Dahle D, Zhou Y, Zhang X, Klibanski A (2005) Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J Clin Endocrinol Metab 90:2179-2186 (Pubitemid 40586259)
21. Pantoja C, de Los Rios L, Matheu A, Antequera F, Serrano M (2005) Inactivation of imprinted genes induced by cellular stress and tumorigenesis. Cancer Res 65:26-33 (Pubitemid 40070792)
22. Benetatos L, Dasoula A, Hatzimichael E, Georgiou I, Syrrou M, Bourantas KL (2008) Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma. Clin Lymphoma Myeloma 8:171-175
23. Benetatos L, Hatzimichael E, Dasoula A, Dranitsaris G, Tsiara S, Syrrou M, Georgiou I, Bourantas KL (2010) CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res 34:148-153
24. Zhang X, Rice K, Wang Y, Chen W, Zhoní Y, Nakayama Y, Zhou Y, Klibanski A (2010) Maternally Expressed Gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions. Endocrinology 151:939-947
25. Hainaut P (1995) The tumor suppressor protein p53: a receptor to genotoxic stress that controls cell growth and survival. Curr Opin Oncol 7:76-82
26. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307-310
27. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296-299 (Pubitemid 27220766)
28. Michael D, Oren M (2003) The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 13:49-58 (Pubitemid 36269180)
29. Joachim T, Ram Z, Rappaport ZH, Simon M, Schramm J, Wiestler OD, von Deimling A (2001) Comparative analysis of the NF2, TP53, PTEN, KRAS, NRAS and HRAS genes in sporadic and radiation-induced human meningiomas. Int J Cancer 94:218-221 (Pubitemid 32911416)
30. Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, Ansell PJ, Zhao J, Weng C, Klibanski A (2007) Activation of p53 by MEG3 non-coding RNA. J Biol Chem 282:24731-24742 (Pubitemid 47347547)
31. Oliner GD, Kinder KW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83
32. Olson D, Marechal V, Momand J, Chen J, Romochi C, Levine AJ (1993) Identification and characterization of multiple mdm2 proteins and mdm2 p53 protein complexes. Oncogene 8:2353-2360 (Pubitemid 23252363)
33. Wu X, Bayle JH, Olson D, Levine AJ (1993) The p53-MDM2 autoregulatory feedback loop. Genes Dev 7:1126-1132
34. Brooks CL, Gu W (2003) Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15:164-171 (Pubitemid 36332191)
35. Momand J, Jung D, Wilczynski S, Niland J (1998) The MDM2 gene amplification database. Nucleic Acids Res 26:3453-3459 (Pubitemid 28347214)
36. Mendrysa SM, O'Leary KA, McElwee MK, Michalowski J, Eisenman RN, Powell DA, Perry ME (2006) Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev 20:16-21 (Pubitemid 43042663)
37. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591-602 (Pubitemid 39535748)
38. Marine JC, Francoz S, Maetens M, Wahl G, Lozano G (2006) Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 13:927-934
39. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J (1996) Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 2:912-917 (Pubitemid 26296763)
40. Bartel F, Taubert H, Harris LC (2002) Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2:9-15 (Pubitemid 41043984)
41. Fridman JS, Hernando E, Hemann MT, de Stanchina E, Cordon-Cardo C, Lowe SW (2003) Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res 63:5703-5706 (Pubitemid 37203378)
42. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, Lozano G (2001) An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 20:4041-4049 (Pubitemid 32681609)
43. Dang J, Kuo ML, Eischen CM, Stepanova L, Sherr CJ, Roussel MF (2002) The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res 62:1222-1230 (Pubitemid 34160312)
44. Brown DR, Thomas CA, Deb SP (1998) The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J 17:2513-2525 (Pubitemid 28221187)
45. Wang YC, Lin RK, Tan YH, Chen JT, Chen CY, Wang YC (2005) Wild-Type p53 Overexpression and Its Correlation With MDM2 and p14ARF Alterations: an Alternative Pathway to Non-Small-Cell Lung Cancer. J Clin Oncol 23:154-164 (Pubitemid 41702634)
46. Onel K, Cordon-Cardo C (2004) MDM2 and prognosis. Mol Cancer Res 2:1-8 (Pubitemid 38167102)
47. Bottner M, Krieglstein K, Unsicker K (2000) The transforming growth factor-betas: structure, signaling, and roles in nervous system development and functions. J Neurochem 75:2227-2240
48. Li P-X, Wong J, Ayed A, Ngo D, Brade AM, Arrowsmith C, Austin RC, Klamut HJ (2000) Placental transforming growth factor-b is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 275:20127-20135 (Pubitemid 30441624)
49. Albertoni M, Shaw PH, Nozaki M, Godard S, Tenan M, Hamou MF, Fairlie DW, Breit SN, Paralkar VM, de Tribolet N, Van Meir EG, Hegi ME (2002) Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastomas cells independently of p53 and HIF-1. Oncogene 21:4212-4219 (Pubitemid 34753827)
50. Xing EP, Yang G-Y, Wang L-D, Shi ST, Yang CS (1999) Loss of heterozygosity of the Rb gene correlates with pRb protein expression and associates with p53 alteration in human esophageal cancer. Clin Cancer Res 5:1231-1240 (Pubitemid 29233242)
51. Jacks T, Weinberg RA (1998) The expanding role of cell cycle regulators. Science 280:1035-1036 (Pubitemid 28234936)
52. Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81:323-330
53. Giacinti C, Giordano A (2006) RB and cell cycle progression. Oncogene 25:5220-5227 (Pubitemid 44299080)
54. Lundberg AS, Weinberg RA (1998) Functional inactivation of the retinoblastoma protein requires sequential modification of retinoblastoma protein by at least two distinct cyclin-Cdk complexes. Mol Cell Biol 18:735-761
55. Sherr C (1996) Cancer cell cycles. Science 274:1672-1677 (Pubitemid 26414890)
56. Mathivanan J, Rohini K, Gope ML, Anandh B, Gope R (2007) Altered structure and deregulated expression of the tumor suppressor gene retinoblastoma (RB1) in human brain tumors. Mol Cell Biochem 302:67-77 (Pubitemid 47202322)
57. Ma D, Zhou P, Harbour JW (2003) Distinct mechanisms for regulating the tumor suppressor and antiapoptotic functions of Rb. J Biol Chem 278:19358-19366 (Pubitemid 36799331)
58. Rassidakis GZ, Lai R, Herling M, Cromwell C, Schmitt-Graeff A, Medeiros LJ (2004) Retinoblastoma protein is frequently absent or phosphorylated in anaplastic large-cell lymphoma. Am J Pathol 164:2259-2267 (Pubitemid 38669371)
59. Al-Khalaf HH, Lach B, Allam A, Hassounah M, Al-Khani A, Elkum N, Alrokayan SA, Aboussekhra A (2008) Expression of survivin and p16INK4a/Cdk6/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells. Brain Res 1188:25-34
60. Simon M, Park TW, Koster G, Mahlberg R, Hackenbroch M, Bostrom J, Loning T, Schramm J (2001) Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression. J Neurooncol 55:149-158 (Pubitemid 34134038)
61. Zhang X, Zhou Y, Klibanski A (2010) Isolation and characterization of novel pituitary tumor related genes: a cDNA representational difference approach. Mol Cell Endocrinol 326:40-47
62. Stork PJ, Schmitt JM (2002) Crosstalk between cAMP and MAPkinase signaling in the regulation of cell proliferation. Trends Cell Biol 12:258-266 (Pubitemid 34634174)
63. Liu X, Ostrom RS, Insel PA (2004) cAMP-elevating agents and adenylyl cyclase overexpression promote an antifibrotic phenotype in pulmonary fibroblasts. Am J Physiol Cell Physiol 286:C1089-C1099 (Pubitemid 38506924)
64. Zhao J, Zhang X, Zhou Y, Ansell PJ, Klibanski A (2006) Cyclic AMP stimulates MEG3 gene expression in cells through a cAMP-response element (CRE) in the MEG3 proximal promoter region. Int J Biochem Cell Biol 38:1808-1820 (Pubitemid 43947661)
65. Benetatos L, Vartholomatos G, Hatzimichael E (2011) MEG3 imprinted gene contribution in tumorigenesis. Int J Cancer 129:773-779
66. Gordon FE, Nutt CL, Cheunsuchon P, Nakayama Y, Provencher KA, Rice KA, Zhou Y, Zhang X, Klibanski A (2010) Increased expression of angiogenic genes in the brains of mouse meg3-null embryos. Endocrinology 151:2443-2452
67. Cavaille J, Seitz H, Paulsen M, Ferguson-Smith AC, Bachellerie JP (2002) Identification of tandemly-repeated C/D snoRNA genes at the imprinted human 14q32 domain reminiscent of those at the Prader-Willi/Angelman syndrome region. Hum Mol Genet 11:1527-1538 (Pubitemid 34679253)
68. Charlier C, Segers K, Wagenaar D, Karim L, Berghmans S, Jaillon O, Shay T, Weissenbach J, Cockett N, Gyapay G, Georges M (2001) Human-ovine comparative sequencing of a 250-kb imprinted domain encompassing the callipyge (clpg) locus and identification of six imprinted transcripts: dLK1, DAT, GTL2, PEG11, anti PEG11 and MEG8. Genome Res 11:850-862 (Pubitemid 32447868)
69. Takada S, Paulsen M, Tevendale M, Tsai CE, Kelsey G, Cattanach BM, Ferguson-Smith AC (2002) Epigenetic analysis of the Dlk1-Gtl2 imprinted domain on mouse chromosome 12: implications for imprinting control from comparison with Igf2-H19. Hum Mol Genet 11:77-86 (Pubitemid 34100770)
70. Lin SP, Youngson N, Takada S, Seitz H, Reik W, Paulsen M, Cavaille J, Ferguson-Smith AC (2003) Asymmetric regulation of imprinting on the maternal and paternal chromosomes at the Dlk1-Gtl2 imprinted cluster on mouse chromosome 12. Nat Genet 35:97-102 (Pubitemid 37048602)
71. Miyazato A, Ueno S, Ohmine K, Ueda M, Yoshida K, Yamashita Y, Kaneko T, Mori M, Kirito K, Toshima M, Nakamura Y, Saito K, Kano Y, Furusawa S, Ozawa K, Mano H (2001) Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood 98:422-427
72. Tsibris JC, Segars J, Coppola D, Mane S, Wilbanks GD, O'Brien WF, Spellacy WN (2002) Insights from gene arrays on the development and growth regulation of uterine leiomyomata. Fertil Steril 78:114-121 (Pubitemid 34722680)
73. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, Johnstone CN, Megraw MS, Adams S, Lassus H, Huang J, Kaur S, Liang S, Sethupathy P, Leminen A, Simossis VA, Sandaltzopoulos R, Naomoto Y, Katsaros D, Gimotty PA, DeMichele A, Huang Q, Bützow R, Rustgi AK, Weber BL, Birrer MJ, Hatzigeorgiou AG, Croce CM, Coukos G (2008) Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 105:7004-7009 (Pubitemid 351754520)
74. Wang P, Ren Z, Sun P (2012) Overexpression of the Long Non-coding RNA MEG3 Impairs In vitro Glioma Cell Proliferation. J Cell Biochem 113:1868-1874
75. Gejman R, Batista DL, Zhong Y, Zhou Y, Zhang X, Swearingen B, Stratakis CA, Hedley-Whyte ET, Klibanski A (2008) Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 93:4119-4125
76. Aypar U, Morgan WF, Baulch JE (2011) Radiation-induced epigenetic alterations after low and high LET irradiations. Mutat Res 707:24-33